RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.13/1532 |
Resumo: | In this study, cyclic arginine-glycine-aspartic acid (RGD) peptide-modified amine-terminated generation 5 poly(amidoamine) (G5.NH2 PAMAM) dendrimers were prepared for the encapsulation of the anticancer drug doxorubicin (DOX) for targeted delivery to cancer cells overexpressing αvβ3 integrin cell surface receptors. First, the thiolated RGD peptide was linked to polyethylene glycol (PEG) via the bifunctional cross-linking reagent 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS). Then a dendrimer modification process was performed in which the PEGylated RGD peptide and fluorescein isothiocyanate (FI) were covalently attached to the G5 dendrimers. This process was finally followed by acetylation of the remaining dendrimer terminal amines. The experimental results show that each G5.NHAc-FI-PEG-RGD dendrimer approximately encapsulated six DOX molecules. This formed complex is water soluble and stable. In vitro release studies proved that the multifunctional dendrimers facilitate a sustained release of DOX. More interesting, one-dimensional NMR and two-dimensional NMR were applied to investigate the interactions between dendrimers and DOX. Here, the impact of the environmental pH on the release rate of DOX from G5.NHAc-FI-PEG-RGD/DOX was fully studied. Furthermore, cell biological studies demonstrated that G5.NHAc-FI-PEG-RGD dendrimers have no cytotoxicity towards U87-MG cancer cells but that G5.NHAc-FI-PEG-RGD/DOX complexes have almost the same cytotoxicity as DOX alone. Moreover, due to the targeting ability of RGD, this dendrimer/drug system can also specifically target and display therapeutic efficacy to cancer cells overexpressing αvβ3 integrins. The cellular internalization of the multifunctionalized dendrimer was shown to be receptor mediated to an important extent. According to this study, we can say that G5.NHAc-FI-PEG-RGD is a promising system for the targeted therapy of different types of cancer. |
id |
RCAP_8b8fdbf9f08680579c7745406951516e |
---|---|
oai_identifier_str |
oai:digituma.uma.pt:10400.13/1532 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cellsDendrimersRGD peptideDoxorubicinTargeted cancer therapyDendrímerosPéptidos RGDDoxorubicinaTerapia do cancro dirigidaNanochemistry and Nanomaterials.Faculdade de Ciências Exatas e da EngenhariaDomínio/Área Científica::Engenharia e Tecnologia::Engenharia dos MateriaisDomínio/Área Científica::Ciências Médicas::Biotecnologia MédicaIn this study, cyclic arginine-glycine-aspartic acid (RGD) peptide-modified amine-terminated generation 5 poly(amidoamine) (G5.NH2 PAMAM) dendrimers were prepared for the encapsulation of the anticancer drug doxorubicin (DOX) for targeted delivery to cancer cells overexpressing αvβ3 integrin cell surface receptors. First, the thiolated RGD peptide was linked to polyethylene glycol (PEG) via the bifunctional cross-linking reagent 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS). Then a dendrimer modification process was performed in which the PEGylated RGD peptide and fluorescein isothiocyanate (FI) were covalently attached to the G5 dendrimers. This process was finally followed by acetylation of the remaining dendrimer terminal amines. The experimental results show that each G5.NHAc-FI-PEG-RGD dendrimer approximately encapsulated six DOX molecules. This formed complex is water soluble and stable. In vitro release studies proved that the multifunctional dendrimers facilitate a sustained release of DOX. More interesting, one-dimensional NMR and two-dimensional NMR were applied to investigate the interactions between dendrimers and DOX. Here, the impact of the environmental pH on the release rate of DOX from G5.NHAc-FI-PEG-RGD/DOX was fully studied. Furthermore, cell biological studies demonstrated that G5.NHAc-FI-PEG-RGD dendrimers have no cytotoxicity towards U87-MG cancer cells but that G5.NHAc-FI-PEG-RGD/DOX complexes have almost the same cytotoxicity as DOX alone. Moreover, due to the targeting ability of RGD, this dendrimer/drug system can also specifically target and display therapeutic efficacy to cancer cells overexpressing αvβ3 integrins. The cellular internalization of the multifunctionalized dendrimer was shown to be receptor mediated to an important extent. According to this study, we can say that G5.NHAc-FI-PEG-RGD is a promising system for the targeted therapy of different types of cancer.Neste trabalho, foram preparados dendrímeros de poli(amidoamina) (PAMAM) de geração 5 (G5) funcionalizados com o péptido cíclico RGD para o encapsulamento do fármaco anticancerígeno doxorubicina (DOX) e sua entrega em células cancerígenas que expressem elevadas quantidades de integrinas αvβ3 na sua superfície (entrega específica do fármaco em células-alvo). No processo de síntese, o péptido contendo um grupo tiol foi primeiro ligado a uma cadeia de polietilenoglicol (PEG) através de um reagente de reticulação bi-funcional. De seguida, os dendrímeros foram ligados covalentemente ao péptido PEGilado e, ainda, ao isotiocianato de fluoresceína (FI), seguindo-se a acetilação (Ac) das aminas terminais remanescentes no dendrímero para se obter o sistema final G5.NHAc-FI-PEG-RGD. Os resultados experimentais mostram que, aproximadamente, existem 6 moléculas de DOX encapsuladas por G5.NHAc-FI-PEG-RGD, sendo estes complexos solúveis e estáveis em água. Os estudos in vitro mostraram que a libertação do fármaco a partir dos dendrímeros multifuncionalizados é controlada. O trabalho envolveu, ainda, estudos de NMR mono- e bi-dimensional na investigação da interacção existente entre os dendrímeros e as moléculas de DOX, e ainda a avaliação do impacto do pH ambiental na velocidade de libertação da DOX. Realizaram-se, igualmente, estudos biológicos com células U87-MG, os quais mostraram que os sistemas G5.NHAc-FI-PEG-RGD não apresentavam toxicidade e que, quando complexados com a DOX, apresentavam uma citotoxicidade semelhante à do fármaco usado de forma isolada. Dada a afinidade do péptido RGD para as integrinas presentes em grande quantidade à superfície das células U87-MG, o sistema G5.NHAc-FI-PEG-RGD mostrou-se muito eficaz na entrega específica do fármaco e consequente eficácia terapêutica. A entrega do fármaco nas células mostrou ser, numa importante extensão, mediada pelos receptores (integrinas αvβ3) presentes à sua superfície. Este trabalho mostrou que os dendrímeros multifuncionalizados G5.NHAc-FI-PEG-RGD são RESUMO vi bastante promissores como sistemas para a entrega específica de fármacos em células cancerígenas.Xiangyang, ShiTomás, Helena Maria Pires GasparDigitUMaXuedan, He2017-06-15T00:30:08Z2014-07-302014-07-30T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.13/1532TID:201648245enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-04-02T05:42:55Zoai:digituma.uma.pt:10400.13/1532Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:04:14.778015Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
title |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
spellingShingle |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells Xuedan, He Dendrimers RGD peptide Doxorubicin Targeted cancer therapy Dendrímeros Péptidos RGD Doxorubicina Terapia do cancro dirigida Nanochemistry and Nanomaterials . Faculdade de Ciências Exatas e da Engenharia Domínio/Área Científica::Engenharia e Tecnologia::Engenharia dos Materiais Domínio/Área Científica::Ciências Médicas::Biotecnologia Médica |
title_short |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
title_full |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
title_fullStr |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
title_full_unstemmed |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
title_sort |
RGD-Modified dendrimers for drug encapsulation and targeted inhibition of tumor cells |
author |
Xuedan, He |
author_facet |
Xuedan, He |
author_role |
author |
dc.contributor.none.fl_str_mv |
Xiangyang, Shi Tomás, Helena Maria Pires Gaspar DigitUMa |
dc.contributor.author.fl_str_mv |
Xuedan, He |
dc.subject.por.fl_str_mv |
Dendrimers RGD peptide Doxorubicin Targeted cancer therapy Dendrímeros Péptidos RGD Doxorubicina Terapia do cancro dirigida Nanochemistry and Nanomaterials . Faculdade de Ciências Exatas e da Engenharia Domínio/Área Científica::Engenharia e Tecnologia::Engenharia dos Materiais Domínio/Área Científica::Ciências Médicas::Biotecnologia Médica |
topic |
Dendrimers RGD peptide Doxorubicin Targeted cancer therapy Dendrímeros Péptidos RGD Doxorubicina Terapia do cancro dirigida Nanochemistry and Nanomaterials . Faculdade de Ciências Exatas e da Engenharia Domínio/Área Científica::Engenharia e Tecnologia::Engenharia dos Materiais Domínio/Área Científica::Ciências Médicas::Biotecnologia Médica |
description |
In this study, cyclic arginine-glycine-aspartic acid (RGD) peptide-modified amine-terminated generation 5 poly(amidoamine) (G5.NH2 PAMAM) dendrimers were prepared for the encapsulation of the anticancer drug doxorubicin (DOX) for targeted delivery to cancer cells overexpressing αvβ3 integrin cell surface receptors. First, the thiolated RGD peptide was linked to polyethylene glycol (PEG) via the bifunctional cross-linking reagent 6-maleimidohexanoic acid N-hydroxysuccinimide ester (MHS). Then a dendrimer modification process was performed in which the PEGylated RGD peptide and fluorescein isothiocyanate (FI) were covalently attached to the G5 dendrimers. This process was finally followed by acetylation of the remaining dendrimer terminal amines. The experimental results show that each G5.NHAc-FI-PEG-RGD dendrimer approximately encapsulated six DOX molecules. This formed complex is water soluble and stable. In vitro release studies proved that the multifunctional dendrimers facilitate a sustained release of DOX. More interesting, one-dimensional NMR and two-dimensional NMR were applied to investigate the interactions between dendrimers and DOX. Here, the impact of the environmental pH on the release rate of DOX from G5.NHAc-FI-PEG-RGD/DOX was fully studied. Furthermore, cell biological studies demonstrated that G5.NHAc-FI-PEG-RGD dendrimers have no cytotoxicity towards U87-MG cancer cells but that G5.NHAc-FI-PEG-RGD/DOX complexes have almost the same cytotoxicity as DOX alone. Moreover, due to the targeting ability of RGD, this dendrimer/drug system can also specifically target and display therapeutic efficacy to cancer cells overexpressing αvβ3 integrins. The cellular internalization of the multifunctionalized dendrimer was shown to be receptor mediated to an important extent. According to this study, we can say that G5.NHAc-FI-PEG-RGD is a promising system for the targeted therapy of different types of cancer. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-07-30 2014-07-30T00:00:00Z 2017-06-15T00:30:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.13/1532 TID:201648245 |
url |
http://hdl.handle.net/10400.13/1532 |
identifier_str_mv |
TID:201648245 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129912024498176 |